

██████████
British Association for Paediatric Nephrology
Birmingham Children's Hospital NHS Foundation Trust
Steelhouse Lane
Birmingham
B4 6NH

By email to: ██████████

18 February 2016

Dear ██████████ and colleagues

**Final Appraisal Determination: immunosuppressive therapy for kidney transplantation
in children and young people**

Thank you for your letter of 4 February in response to my initial scrutiny letter of 28 January. I am grateful for your clarification that the BAPN's and BTS' appeal under Ground 2 against recommendation 1.4 of the above Final Appraisal Determination does not include belatacept and everolimus.

I can now give you my final scrutiny decision. As I noted in my initial scrutiny letter, I consider that all the points made in the BAPN's and BTS' original letter are valid appeal points except that relating to NHS England's processes and switching therapies. With that exception, your points will be heard at an oral hearing, details of which have been separately notified to you.

Yours sincerely

Andy McKeon
Vice Chair
National Institute for Health and Care Excellence